IL-21 in cancer immunotherapy

IL-21 isoform is a membrane-bound ligand and activates directly interacted cells

(2013) Hidetoshi Nara et al.   CYTOKINE

Increased cytotoxic capacity of tumor antigen specific human T cells after in vitro stimulation with IL21 producing dendritic cells

(2013) A.W. Turksma et al.   HUMAN IMMUNOLOGY

IL-21 promotes the expansion of CD27+CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells

(2013) Saskia JAM Santegoets et al.   Journal of Translational Medicine

Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients

(2013) A. G. Chapuis et al.   Science Translational Medicine

Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails

(2012) Shicheng Yang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study

(2012) Teresa M. Petrella et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions

(2012) Ayumi Yoshizaki et al.   NATURE

Interleukin-21 in cancer immunotherapy

(2012) Carmine Stolfi et al.   OncoImmunology

Dissociation of Its Opposing Immunologic Effects Is Critical for the Optimization of Antitumor CD8+ T-Cell Responses Induced by Interleukin 21

(2008) S. Ansen et al.   CLINICAL CANCER RESEARCH